Logo image of UNCY

UNICYCIVE THERAPEUTICS INC (UNCY) Stock Fundamental Analysis

USA - NASDAQ:UNCY - US90466Y2028 - Common Stock

4.71 USD
-0.22 (-4.46%)
Last: 10/17/2025, 8:00:01 PM
4.6301 USD
-0.08 (-1.7%)
After Hours: 10/17/2025, 8:00:01 PM
Fundamental Rating

2

UNCY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. UNCY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. UNCY has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

UNCY had negative earnings in the past year.
UNCY had a negative operating cash flow in the past year.
In the past 5 years UNCY always reported negative net income.
UNCY had a negative operating cash flow in each of the past 5 years.
UNCY Yearly Net Income VS EBIT VS OCF VS FCFUNCY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -119.44%, UNCY is doing worse than 79.25% of the companies in the same industry.
UNCY has a worse Return On Equity (-509.00%) than 77.76% of its industry peers.
Industry RankSector Rank
ROA -119.44%
ROE -509%
ROIC N/A
ROA(3y)-327.07%
ROA(5y)-432.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
UNCY Yearly ROA, ROE, ROICUNCY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K

1.3 Margins

UNCY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UNCY Yearly Profit, Operating, Gross MarginsUNCY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

5

2. Health

2.1 Basic Checks

UNCY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, UNCY has more shares outstanding
The number of shares outstanding for UNCY has been increased compared to 5 years ago.
UNCY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
UNCY Yearly Shares OutstandingUNCY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
UNCY Yearly Total Debt VS Total AssetsUNCY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -5.51, we must say that UNCY is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.51, UNCY is doing worse than 63.36% of the companies in the same industry.
UNCY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.51
ROIC/WACCN/A
WACC9.35%
UNCY Yearly LT Debt VS Equity VS FCFUNCY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

UNCY has a Current Ratio of 1.28. This is a normal value and indicates that UNCY is financially healthy and should not expect problems in meeting its short term obligations.
UNCY's Current ratio of 1.28 is on the low side compared to the rest of the industry. UNCY is outperformed by 84.49% of its industry peers.
A Quick Ratio of 1.28 indicates that UNCY should not have too much problems paying its short term obligations.
UNCY's Quick ratio of 1.28 is on the low side compared to the rest of the industry. UNCY is outperformed by 83.36% of its industry peers.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 1.28
UNCY Yearly Current Assets VS Current LiabilitesUNCY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

UNCY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.88%, which is quite impressive.
The Revenue for UNCY has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)62.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.33%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

UNCY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.37% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y83.44%
EPS Next 2Y116.72%
EPS Next 3Y55.69%
EPS Next 5Y26.37%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
UNCY Yearly Revenue VS EstimatesUNCY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
UNCY Yearly EPS VS EstimatesUNCY Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for UNCY. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 0.16 indicates a rather cheap valuation of UNCY.
Based on the Price/Forward Earnings ratio, UNCY is valued cheaply inside the industry as 99.63% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.94. UNCY is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 0.16
UNCY Price Earnings VS Forward Price EarningsUNCY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UNCY Per share dataUNCY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as UNCY's earnings are expected to grow with 55.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y116.72%
EPS Next 3Y55.69%

More info and screens

0

5. Dividend

5.1 Amount

UNCY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNICYCIVE THERAPEUTICS INC

NASDAQ:UNCY (10/17/2025, 8:00:01 PM)

After market: 4.6301 -0.08 (-1.7%)

4.71

-0.22 (-4.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)N/A N/A
Inst Owners31.05%
Inst Owner Change0%
Ins Owners3.56%
Ins Owner Change0%
Market Cap83.18M
Analysts82.86
Price Target64.39 (1267.09%)
Short Float %8.85%
Short Ratio3.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP-2.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-57.77%
Min EPS beat(2)-183.22%
Max EPS beat(2)67.68%
EPS beat(4)2
Avg EPS beat(4)-94.53%
Min EPS beat(4)-285.83%
Max EPS beat(4)67.68%
EPS beat(8)3
Avg EPS beat(8)-69%
EPS beat(12)3
Avg EPS beat(12)-55.72%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)22.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-71.72%
EPS NY rev (1m)31.68%
EPS NY rev (3m)14.03%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-77.11%
Revenue NY rev (3m)-94.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.16
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 11.19
P/tB 11.19
EV/EBITDA N/A
EPS(TTM)-4.12
EYN/A
EPS(NY)28.86
Fwd EY612.65%
FCF(TTM)-1.62
FCFYN/A
OCF(TTM)-1.62
OCFYN/A
SpS0
BVpS0.42
TBVpS0.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -119.44%
ROE -509%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-327.07%
ROA(5y)-432.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 327.27%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.28
Quick Ratio 1.28
Altman-Z -5.51
F-Score4
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)153.54%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.33%
EPS Next Y83.44%
EPS Next 2Y116.72%
EPS Next 3Y55.69%
EPS Next 5Y26.37%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-54.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.38%
EBIT Next 3Y175.15%
EBIT Next 5YN/A
FCF growth 1Y-56.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.29%
OCF growth 3YN/A
OCF growth 5YN/A